LOGIN  |  REGISTER
Amneal Pharmaceuticals
C4 Therapeutics

Cipher Pharmaceuticals Schedules Q4 & Fiscal 2024 Earnings Release and Conference Call

March 11, 2025 | Last Trade: C$15.73 0.20 -1.26

MISSISSAUGA, ON, March 11, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the fourth quarter and fiscal 2024 after the market close on Tuesday, March 18, 2025. The Company will also hold a conference call on Wednesday, March 19, 2025 at 8:30am ET to discuss the results and corporate developments.

CONFERENCE CALL DETAILS

DATE:

Wednesday, March 19, 2025

TIME:

8:30 a.m. ET

DIAL-IN NUMBER:

416-945-7677 or 888-699-1199

REPLAY:

289-819-1450 or 888-660-6345 Code: 49540#

 

Expires: March 26, 2025

WEBCAST:

https://app.webinar.net/A3drRqWpovk

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America. For more information, visit www.cipherpharma.com.

Viking Therapeutics

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page